Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (5984)	1/27/1999 1:40:00 AM
From: Steve Fancy	Respond to of 6136

John, you seem to be on the defensive for some reason. I don't dispute any of these facts and don't recall suggesting Johnson was a poor negotiator. I only referenced Remune cause it was next up in the pipeline. You seem to have a handle on the situation...why are they selling at $60. Certainly not out of the kindness of their hearts. sf

To: John Metcalf who wrote (5984)	1/27/1999 1:58:00 AM
From: Steve Fancy	Respond to of 6136

It doesn't make sense John. They were gearing up to go it alone with a separate tracking stock for the Oncology division, the stock started reflecting the potential of the pipeline, then all of a sudden, a change in strategy to sell at basically the current market value. C'mon. Something is wrong with the picture. This is what everyone seems upset about. Myself, I'll take the 60 and be happy. sf

To: John Metcalf who wrote (5984)	1/27/1999 2:49:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 6136

I'm not surprised to see the new contributors to this thread bitch. Those who bought in the neighborhood of 55 and have just recently heard of AGPH must not understand that the deal was in the current price. That's sort of naive, however. I am surprised, however, to hear some of the old-timers complain. When the stock had taken the steep dive to south of 30, I said that there was only one thing to keep your eye on..... the price that someone would pay to access that sales force. At that time, I said in more than one forum that the price would be in the vicinity of $70/share. I'm not bringing that up to show that I made a decent prediction, but to revisit the responses that I got *at that time. Some of those who are bitching now were counting their bucks, and smiling, when people mentioned $70/share (and lower figures). The deal is already in the price, as the company has been shopped. If you'd like to back out of the WL deal and stay independent, fine, but....... if you could do such....... the market would hand you a $35 stock. "AGPH online" got launched in misc.invest.stocks in the Spring of '95. Clive Taylor was there. There were the biotech nuts.... John Metcalf, Rudy Saucillo, Jim Silverman, Dr. John Dwyer, Dr. Mike Solomon, Shahram Mori, Dr. John de Castro, Paul Yadlowski, Ron Bartlett, Dr. Purshotam Bhan, Dr. Jerry McLaughlin, Dr. Mark Henderson, Dr. John Loike, John Fitisoff, Dr. Kevin Jones, and many others. I do not believe that any one of them could have anything other than admiration for the job that Peter Johnson and team have done. I guess you have to come from the frame of "AGPH, and how it was viewed relative to VRTX", circa 1994. So, to all the whiners..... phbbbbbbbbbbbbbbt! The rights to Viracept were obtained from Lilly in January, 1994. You* try taking a company from that stage to a successful small pharma in five years. Margie..... I agree with earlier comments. As you know, I took my Johnson-delivered 10 bagger and split, quite some time ago. Since then, I didn't need to do much research to stay on top of where the issues would take the stock. You held steady throughout all of the fear-mongering, bringing the relevant points to the thread and presenting them in a concise fashion. Thanks! Bottom line with AGPH.... Johnson or Nichols, you got a balanced view of hopes and hurdles.